ADReCS

Pharmaceutical Information

Drug Name	Losartan
Drug ID	BADD_D01322
Description	Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension.[L7423] Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough.[L7423] When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or [hydrochlorothiazide].[L7423] Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide.[L7423,L7426] Patients taking losartan should have their renal function and potassium levels monitored.[L7423] Losartan was granted FDA approval on 14 April 1995.[L7423]
Indications and Usage	Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension.[L7423] Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).[L7426]
Marketing Status	approved
ATC Code	C09CA01
DrugBank ID	DB00678
KEGG ID	D08146
MeSH ID	D019808
PubChem ID	3961
TTD Drug ID	D0DD0K
NDC Product Code	70010-741; 62207-742; 70010-742; 70010-743
UNII	JMS50MPO89
Synonyms	Losartan \| 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol \| DuP-753 \| DuP 753 \| DuP753 \| MK-954 \| MK 954 \| MK954 \| Cozaar \| Losartan Potassium \| Potassium, Losartan \| Losartan Monopotassium Salt \| Monopotassium Salt, Losartan \| Salt, Losartan Monopotassium

Chemical Information

Molecular Formula	C22H23ClN6O
CAS Registry Number	114798-26-4
SMILES	CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Respiratory tract oedema	22.02.07.013	0.000015%		Not Available
Noninfectious peritonitis	07.07.01.005	0.000020%		Not Available
Drug-induced liver injury	12.03.01.044; 09.01.07.023	0.000073%		Not Available
Drug reaction with eosinophilia and systemic symptoms	12.03.01.064; 23.03.05.005; 10.01.01.021	0.000040%		Not Available
Mouth swelling	23.04.01.020; 10.01.05.020; 07.05.04.007	0.000037%		Not Available
Intestinal angioedema	23.04.01.019; 10.01.05.019; 07.08.03.012	0.000045%		Not Available
Anal incontinence	17.05.01.021; 07.01.06.029	0.000044%
Abnormal loss of weight	14.03.02.019	0.000020%		Not Available
Alcohol interaction	08.06.03.003	0.000025%		Not Available
Cerebellar haemorrhage	24.07.04.023; 17.08.01.046	0.000010%		Not Available
Chronic gastritis	11.07.01.016; 10.04.04.011; 07.08.02.005	0.000030%		Not Available
Coeliac disease	14.02.01.007; 10.04.04.012; 07.17.01.008	0.000092%		Not Available
Concomitant disease aggravated	08.01.03.063	0.000015%		Not Available
Renal atrophy	20.01.06.001	0.000010%		Not Available
Symptom masked	08.01.03.078	0.000050%		Not Available
Atrial thrombosis	02.11.01.002; 24.01.05.005	0.000010%		Not Available
Intestinal villi atrophy	07.11.03.010	0.000015%		Not Available
Renal impairment neonatal	20.01.03.025; 18.04.01.020	0.000020%		Not Available
Allergic cough	22.02.03.011; 10.01.03.040	0.000034%		Not Available
Delayed fontanelle closure	15.10.05.003	0.000015%		Not Available
Palatal oedema	07.05.04.008	0.000025%		Not Available
Cell death	08.03.03.003; 14.11.02.005	0.000010%		Not Available
Subacute cutaneous lupus erythematosus	23.03.02.020; 15.06.02.012; 10.04.03.012	0.000020%		Not Available
Hypertensive emergency	24.08.01.004	0.000010%		Not Available
Allergy to arthropod sting	10.01.03.041	0.000015%		Not Available
Bladder mass	20.03.01.018	0.000010%		Not Available
Cranial sutures widening	18.04.01.015; 15.10.05.002	0.000059%		Not Available
Cerebrosclerosis	17.11.01.015	0.000015%		Not Available
Asthmatic crisis	22.03.01.018	0.000015%		Not Available
Spinal pain	08.01.08.030; 17.10.01.020; 15.02.01.008	0.000015%		Not Available

The 15th Page First Pre 15 16 Next Last Total 16 Pages